Reported side effects Nausea (dose-dependent, more common at higher doses) Facial flushing and increased skin warmth Reduced appetite and mild fatigue Spontaneous erections or increased libido in men Injection site reactions (redness, mild stinging) Changes in existing moles Transient increases in heart rate and blood pressure Storage Lyophilised (unmixed) Freeze at -20 C (-4 F) or below, in dry, dark conditions
Improvement in nausea often coincides with dose stabilization and physiologic adaptation, frequently after the first several weeks of therapy or following a slower titration schedule
While its efficacy and safety profile are comparable to oral Wegovy , it falls significantly short of Eli Lillys subcutaneous tirzepatide the gold standard of GLP-1 analogs to date (technically a dual agonist mimicking both GLP-1 and GIP)
Xu P, Lin B, Deng X, Huang K, Zhang Y, Wang N
It is generally recommended for people who are obese or have a body mass index (BMI) of 30 or higher